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Abstract 
 
Background: mhealth, predominantly wearable technology and mobile apps, have been considered in 
Parkinson’s Disease to provide valuable ecological data between face to face visits and improve monitoring 
of motor symptoms remotely.  
Objective: In this study we explore the feasibility of using a technology based mhealth platform 
comprising a smartphone in combination with a smartwatch and a pair of smart insoles, described in the 
present study as the PD_manager system, to collect clinically meaningful data. We also explore outcomes 
and disease related factors which are important determinants to establish feasibility. Finally, we further 
validate a tremor evaluation method with data collected while patients perform their daily activities.  
Methods: PD_manager trial was an open label parallel group randomized study. The mheath platform 
consists of a wristband, a pair of sensor insoles, a smartphone (with dedicated mobile Android apps and a 
knowledge platform) serving as the cloud backend. The compliance was assessed with statistical analysis 
and the factors affecting it using appropriate regression analysis. The correlation of the scores of our 
previous algorithm for tremor evaluation and the respective UPDRS estimations by clinicians were 
explored. 
Results: There were 65 of the 75 study participants (87%) who completed the protocol. They used the 
PD_manager system for a median 11.57 days (Std. dev. 3.15). The regression analysis suggests that the 
main factor associated with high usage was caregivers’ burden. Motor Aspects of Experiences of Daily 
Living and patients’ self-rated health status also influence the system’s usage. Our algorithm provided 
clinically meaningful data for the detection and evaluation of tremor.   
Conclusions: We found that PD patients, regardless of their demographics and disease characteristics, 
used the system for 11-14 days. The study further supports that mhealth can be an effective tool for the 
ecologically valid, passive, unobtrusive monitoring and evaluation of symptoms. Future studies will be 
required to demonstrate that an mhealth platform can improve disease management and care. 
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Introduction 
 
Parkinson’s disease (PD) is a progressive disorder with patients having heterogeneous symptoms and 
progression rates. Presently, there is no cure for the condition and treatment aims at controlling symptoms 
by optimizing medication plans. Optimization and personalization of the treatment is currently based on 
clinical interview, diaries and scales, though in the future it may benefit from information on symptoms 
and medication adherence collected away from the clinic while the patients perform their normal daily 
activities.   
Technology, even with the existing regulatory limitations and barriers, offers the possibility for improved 
care, self-assessment options, and overall improved healthcare outcomes [1] [2]. Wearable sensors and 
mobile apps have been extensively used to monitor and evaluate mainly motor symptoms and motoric 
complications of PD patients in their home environments [3]. However, reliable and unobtrusive solutions 
for non-motor symptoms are still lacking [1].  
Despite the potential benefits of the use of technologies, various important aspects of its feasibility remain 
to be explored. Only a few studies have rigorously investigated the feasibility and utility of using 
technology-based platforms. Moreover, apart from three [2] [4] [5], most prior studies remained limited 
by the small sample sizes (samples of up to 51 PD patients in varying disease stages) [6-11]. Evidence of 
mhealth utility for the clinicians is in its early days even for commercial grade systems [1213]. None of the 
previous studies has systematically explored the role of caregivers in compliance with mhealth.   
In the current analysis, we aimed to investigate the feasibility of using an mhealth platform, described in 
the present study as the PD_manager system, comprising a smartphone, a smartwatch and pair of smart 
insoles. The study focuses on participants’ compliance and their determinants. The study also validates the 
system’s utility to collect clinically meaningful data with ecological validity.  
 
  
3 
 
Methods 
 
Between May 2017 and March 2018, a total of 136 consenting patients with Parkinson’s disease (Hoehn 
and Yahr stage “off” >= 3, experiencing motor fluctuations at least 2 h per day based on UPDRS-IV score), 
with a live-in caregiver, were recruited in three countries (50 Rome, 44 Venice, Italy; 21 in Ioannina, Greece 
and 21 in Surrey, England). Four of them were excluded from the study, two because they withdrew and 
two because they were not eligible at reassessment, leaving a total 75 patients assigned to the PD_manager 
group and 57 to the control group. The PD_manager group characteristics are summarized in Table 1. 
Table 1: PD_manager group characteristics. 
Variable  
Gender (% of females) 40 
Age 67.73 (8.72) 
Years since diagnosis 9.21 (4.41) 
H&Y (% of stage 3 patients) 93.30 
BMI%  26.04  (3.95) 
MMSE 28.60  (1.74) 
MDS-UPDRS III 28.15 (15.06) 
NMSS 45.17 (38.55) 
Values are mean (SD), unless otherwise noted  
In this work we are focusing on the actual system usage and compliance as depicted in the data collected 
from the patients and their caregivers vis-à-vis data collected via the respective PD_manager devices, i.e. 
we are analyzing only the PD_manager group. Focus is on compliance metrics as well as the factors 
affecting the compliance. Moreover, we provide evidence that the data are clinically meaningful since they 
can be used for accurately monitoring and evaluating symptoms and specifically tremor.  
 
Study design  
The PD_manager trial [14] was an open label parallel group randomized study. It was conducted to assess 
the feasibility, usability and the trends of effectiveness of the PD_manager system, compared to traditional 
practices of using a symptom diary, for the management of people with Parkinson’s disease.  
Following informed consent, baseline information was gathered, including the following: age, gender, 
education, attitudes to technology (patient and caregiver), time since Parkinson’s diagnosis, symptom 
status (with NMSS and UPDRS), comorbidities (patient only), caregiver burden (Short Zarit), patient’s 
self-assessment of the disease (EQ-5D-5L) and patient’s self-assessed quality of life (PDQ-8).  
The patients were asked to use the system for 14 days continuously during 12 hours daytime. The 14 days 
duration for the wearing of study devices (wristband and smartphone) by participants, was defined for a 
number of reasons. First, it was based on analysis of user needs, safeguarding ethics and privacy, as well 
as the burden on study participants. Second, it was considered enough for collection of sufficient data to 
provide clinically meaningful information. Finally, findings of previous larger studies [5], with similar 
investigation concepts, indicated that around 70% of the patients were compliant for up to 15 days. 
During the 14-days period the system passively and automatically captured raw sensor data (from the 
smartphone, the wristband and the insoles) to be used for the evaluation of motor symptoms, aggregated 
data on sleep and activity (wristband proprietary software), speech, cognitive status and emotional state 
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using the smartphone apps (with scheduled prompts-notifications for the user to perform specific tasks). 
The smartphone was used for storing the data locally. Automatic transmission of the data to a cloud 
backend was possible but not used during the pilot for privacy and security purposes. Control group 
participants were asked to keep a motor symptom diary for 3 days and complete the Parkinson’s Well-
Being Map. After a minimum of two weeks, a specialist doctor reviewed the data gathered. Participants, 
caregivers and clinicians were asked for feedback on the acceptability and utility of the data collection 
methods. Data collection for the whole pilot study is summarized in Table 2. 
Table 2: Summary of PD_manager group data collection at each stage. 
Participant 
group 
 Data capture at each stage 
  Baseline During intervention, 
PD_manager group 
from devices 
Post-intervention, 2-
week follow-up 
Patient Age, gender, education, disease 
duration, disease stage (Hoehn and 
Yahr score), main symptoms 
(tremor, bradykinesia, rigidity, 
dyskinesia), more affected side, 
UPDRS scores, current medications, 
comorbidities, views on technology 
(with the Technology Assessment 
Model). 
Outcomes: EQ-5D-5L; PDQ-8; 
NMSS, UPDRS. 
Motor symptoms 
(gait, freezing of 
gait, bradykinesia, 
dyskinesia, activity); 
non-motor 
symptoms 
(cognition, sleep, 
mood). 
Interviews on 
acceptability and ease 
of use of PD_manager 
or symptom diary. 
Data collected in the 
smartphone and in the 
backend from 
smartphone and 
wristband sensors, 
data from insoles 
stored in the backend. 
Caregiver Age, gender, education, views on 
technology (with the Technology 
Acceptance Model).  
Outcome: Zarit Caregiver Burden 
Scale (using short version). 
No information is 
collected from 
caregivers in the 
PD_manager group. 
Interviews on 
acceptability and ease 
of use of PD_manager 
or symptom diary. 
Clinician Technophobia, previous experience 
with monitoring technology, socio-
demographics, clinical experience 
- System Usability Scale 
(SUS), Post-Study 
System Usability 
Questionnaire 
(PSSUQ), Technology 
Acceptance Modified 
Model (TAMM). 
 
5 
 
The mhealth platform 
The mheath platform depicted in Figure 1 has been described in detail in a previous work [15] and consists 
of a wristband (Microsoft Band, Microsoft Corporation, Redmond, WA, USA), a pair of sensor insoles 
(Moticon GmbH, Munich, Germany), a smartphone (Aquaris M and U models, BQ, Madrid, Spain) with 
dedicated mobile Android apps (see Figure 2) and a knowledge platform (hosted by Biotronics 3D, London, 
UK) serving as the cloud backend of the platform. The Microsoft Band SDK allowed us to access data from 
the Band’s sensors.  The wristband and the smartphone provided raw data from the 3-axis accelerometer 
and the gyroscope at a sampling rate of 100 Hz that were used for building motor symptoms’ assessment 
methods. The Band could also be used for collecting heart rate, galvanic skin response and skin 
temperature data. Moreover, the accompanying Microsoft Health App provided aggregated data for sleep 
(sleep duration, number of wakeups, ratio of time asleep to total sleep, total length of restless and restful 
sleep in minutes) and activity (type e.g. Run, Sleep, Bike, summary of calories burned, summary of heart 
rate data). With the insoles we collected pressure distribution and accelerometer data enabling us to 
evaluate weight-bearing, balance and motion sequences and study gait. 
Data from devices were transferred and stored in a web-based cloud, NoSQL database in anonymised and 
encrypted format. The servers storing the information in the cloud platform are based on Biotronics 3D’s 
3DnetMedical platform in an ISO27001-accredited data centre located in London. They are operated in 
accordance with the Data Protection Act.  
 
Figure 1: PD_manager mhealth platform overview. 
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Figure 2: Screenshots from the patients' mobile application. From left to right: the list with the tasks the patient has to 
perform, some cognitive tests, the finger tapping test, mood monitoring diary. 
During the pilot study, the participants were instructed to always carry the smartphone with them since 
the wristband needs to be paired with the phone through the Bluetooth connection for transmitting and 
storing wristband data. Two optimization strategies were applied in order to reach the desired MS Band 
battery daily duration of 12-14 hours and address battery drain issues: a) by default, the application 
acquires data for a period of 5 minutes and then disconnects from MS Band (closing Bluetooth and 
therefore reducing significantly the MS Band power consumption)) for a period of X minutes, where X is 
estimated based on the hours of the required recording interval which is customized in the application 
settings; b) when the patient removes the MS Band (detected with HR quality value) then the data 
acquisition is postponed. Moreover, study participants were instructed to use the system as much as 
possible during the waking day while performing daily activities and charge it just before going to sleep. 
The insoles had their internal storage capability. 
The devices are unobtrusive. Their wearability, sensitivity and reliability were tested as part of an earlier 
proof of concept study [16] with 20 patients (5 Rome, 10 Venice, Italy; 5 Ioannina, Greece). This proof-of-
concept study was supervised by neurologists in an in-hospital setting and involved short sessions (154 in 
total, each one lasting around 30’) following a common protocol that included simulation of daily activities 
such as opening a door, drinking water, walking a few meters, rising from a chair and rising from the bed.  
The nutrition and physiotherapy modules were evaluated in separate studies [17]. 
The clinicians had their dedicated mobile app (see Figure 3) that enabled them to check the demographic 
and clinical information, assess the overall status of the patient, evaluate symptoms monitored during the 
pilot period and get decision support functionalities [18] on patients mobility. 
 
 
 
   
 
 
 
   
 
 
 
 
Figure 1: Cognitive tests. 
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Figure 3: Screenshots from the clinicians' mobile app. From left to right: Overview of clinical information, scores from scales 
and tests, overview of motor symptoms as assessed by the PD_manager methods for the whole day and creating new 
medication orders. To ensure that there are no risks for the participants, we omitted the medication adherence module (both 
the mobile app and the pillbox) from the pilot. 
  
Outcome definitions and statistical analysis 
Feasibility assessment includes recruitment, compliance and evaluation of the processed sensor data utility 
for answering clinically meaningful questions. Recruitment success was analyzed by the total number of 
enrolled, consenting participants that completed the pilot study against drop-outs. Compliance was 
calculated as the total hours where band and smartphone sensors data were collected during the 14 days 
period, as well as number of days during which the participants used the system for at least one hour.  
The statistical analysis investigates the effects of the patient demographics (age, gender, education), 
clinical symptoms (as depicted in NMMS and UPDRS), self-rated quality of life (PDQ8 and EQ-5D-5L), 
caregivers’ demographics (age, gender, education) and burden (as captured with the short version of Zarit) 
on the system usage as reflected in the total usage hours over the 14 days data collection period by the 
devices for each participant. In this targeted analysis we have included only the 65 of the originally 
recruited 75 participants, for which duration of data collected is at least one day of the pilot period.  The 
study data were analyzed by SPSS software (version 23, IBM Corporation, Armonk, NY, USA).   
Compliance was not normally distributed. Correlations between compliance and the available at-baseline 
information for the participants were explored with Spearman's rank-order and Kendall's tau-b. 
Participants were then divided in low-moderate-high usage groups using the quartiles (the first quartile 
was the cut-off for the low compliant group and third quartile for the high compliant group) and taking 
into account qualitative information, mainly band usage - which was another metric available for 
compliance evaluation - for confirming the grouping. Significant differences in the distributions of usage 
between compliance groups were investigated with Kruskal-Wallis H test for the low-moderate-high 
groups.  
To further investigate the factors affecting compliance, regression analysis was applied. Linear Regression 
determined how much of the variation in the usage is explained by the caregiver burden. Multiple Linear 
Regression determined how much of the variation in the system usage is explained by the caregivers’ 
burden, Motor Aspects of Experiences of Daily Living and patients’ self-rated health status. Binary Logistic 
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Regression explored the effects of the same parameters on the likelihood of usage, predicting the moderate-
high groups. 
Validation of the tremor method was done with bivariate correlations between UPDRS items scored be the 
clinicians at baseline and the tremor score with our method were calculated with Pearson’s.  A Welch t-test 
was also run to determine if there were differences in scores between the no-tremor and tremor groups. 
The statistical methods used in the analysis are depicted in Figure 4. 
 
 
Figure 4: Outcome definitions and statistical analysis. 
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Results 
 
Recruitment 
From the 75 patients that were eligible and consented to participate in the study and were randomly 
assigned to the PD_manager group, 65 (87% of the group), were data providers with at least one day of 
system usage. The other 10 either chose not to use the system or due to technical reasons (Bluetooth 
disconnection) were unable to use it.  
Compliance 
The 65 data-contributors collected data for a median of 63,37 (Std. dev. 42,17) hours totally in the 14-days 
study period. i.e. 4,53 hours on average per day. They used the system for a median 11,57 days (Std. dev. 
3,15). Only two of the study participants used the system for one day. All others used it for more than 6 
days with 30 using it for the whole 14 days study period. 
Sample characteristics and bivariate correlations 
The study sample characteristics are presented in Table 3. Most participants had many symptoms as 
reflected in UPDRS total and sub-scores. Most study participants were men (almost 2:1), while for 
caregivers the reverse was observed (women 2:1). Caregivers were slightly more educated (11.96 years) 
compared to study participants (10.18), which can be explained from the fact that 27% were children or 
nephews. For the same reason the caregivers were younger (mean 60). UPDRS score (mean 56,45) is 
consistent with the severity of the condition. Participants did not have dementia (based on MMSE and 
iADL). 
Table 3: Analysis of distributions between groups. 
 High Group (N = 21) Moderate Group (N = 28) Low Group (N = 16)  
 
Mean  
(Std 
Dev.) 
Correlation 
Coefficient, p 
(Spearman) 
Mean  
(Std 
Dev.) 
Correlation 
Coefficient, p 
(Spearman) 
Mean  
(Std 
Dev.) 
Correlation 
Coefficient, p 
(Spearman) 
Distribution 
χ2(2), p 
(Kruskal 
Wallis) 
Usage hours 
108.29 
(37.50) 
 
58.93 
(18.47) 
 
19.19 
(7.63) 
 - 
Days of usage 
13.52 
(1.03) 
0.103 (0.658) 
11.21 
(2.59) 
-0.030 
(0.880) 
9.63 
(4.40) 
0.340 (0.198) 14.843 (0.001) 
Caregiver age 
60.00 
(13.09) 
0.188 (0.427) 
58.38 
(12.06) 
0.171 (0.403) 
63.50 
(10.83) 
-0.151 (0.639) 2.138 (0.343) 
Caregiver 
education 
10.89 
(4.90) 
-0.263 
(0.276) 
12.50 
(5.02) 
0.127 (0.536) 
12.60 
(4.20) 
0.091 (0.802) 0.677 (0.713) 
Caregiver gender  14 female, 7 male 
14 female, 11 male, 3 
missing 
10 female, 4 male, 2 
missing 
1.057 (0.590) 
Patient age 
67.24 
(6.71) 
-0,232 
(0.312) 
67.67 
(11.45) 
0.186 (0.352) 
67.69 
(6.02) 
-0.457 (0.075) 0.105 (0.949) 
Patient gender 5 female, 16 male 14 female, 14 male 4 female, 12 male  
Patient education 
9.50 
(4.87) 
-0.419 
(0.066) 
10.48 
(4.23) 
0.002 (0.992) 
10.50 
(5.07) 
0.068 (0.803) 0.274 (0.872) 
Disease duration 
8.90 
(5.04) 
0.044 (0.854) 
9.18 
(4.67) 
-0.080 
(0.685) 
8.44 
(3.08) 
-0.338 
(0.200) 
0.005 (0.998) 
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MMSE 
28.32 
(1.70) 
0.577 (0.010) 
28.79 
(2.13) 
0.174 (0.375) 
28.40 
(1.24) 
-0.264 
(0.343) 
0.876 (0.645) 
EQ-5D-5L Total 
9.48 
(3.63) 
-0.203 
(0.378) 
10.54 
(3.42) 
0.056 (0.778) 
9.87 
(2.70) 
-0.132 (0.640) 0.988 (0.610) 
NMSS Total 
42.09 
(29.43) 
-0.163 
(0.480) 
44.00 
(34.85) 
0.210 (0.292) 
39.07 
(17.62) 
0.296 (0.305) 0.195 (0.907) 
PDQ8 Total 
41.25 
(18.41) 
-0.098 
(0.681) 
43.29 
(23.95) 
0.190 (0.343) 
39.58 
(17.30) 
0.324 (0.239) 0.179 (0.914) 
UPDRS I Total 
10.81 
(6.65) 
-0.053 
(0.818) 
11.11 
(5.42) 
0.119 (0.547) 
11.00 
(4.40) 
-0.170 (0.561) 0.280 (0.869) 
UPDRS II Total 
13.14 
(9.14) 
-0.039 
(0.867) 
10.54 
(7.39) 
0.349 (0.068) 
8.36 
(6.01) 
-0.313 (0.276) 2.425 (0.297) 
UPDRS III Total 
29.67 
(17.46) 
-0.079 
(0.733) 
28.85 
(15.28) 
0.199 (0.319) 
25.67 
(13.93) 
0.083 (0.768) 0.540 (0.763) 
UPDRS IV Total 
5.76 
(3.90) 
0.232 (0.312) 
5.93 
(4.60) 
0.074 (0.710) 
5.58 
(3.44) 
0.441 (0.115) 0.053 (0.974) 
UPDRS Total 
59.38 
(30.74) 
0.022 (0.924) 
56.70 
(28.10) 
0.213 (0.286) 
51.57 
(24.67) 
-0.076 (0.795) 0.682 (0.711) 
Zarit Total 
14.67 
(9.90) 
0.283 (0.213) 
8.92 
(6.93) 
0.206 (0.313) 
10.64 
(7.22) 
-0.202 
(0.489) 
4.290 (0.117) 
 
EQ-5D-5L item 4 
(pain/ 
discomfort) 
1.81 
(0.87) 
-0.072 
(0.758) 
2.64 
(0.95) 
-0.110 (0.579) 
2.33 
(0.90) 
0.112 (0.692) 8.519 (0.014) 
NMSS item 11 
(flat moods) 
1.33 
(1.96) 
0.105 (0.650) 
1.07 
(2.22) 
0.179 (0.371) 
0.071 
(0.27) 
-0.069 (0.815) 7.353 (0.025) 
NMSS item 26 
(problems having 
sex) 
2.24 
(4.19) 
-0.308 (0.174) 
0.82 
(3.14) 
0.115 (0.569) 
0.36 
(1.08) 
0.094 (0.749) 6.192 (0.045) 
PDQ8 item 7 
(painful cramps 
or spasms) 
1.7 (1.22) 
-0.005 
(0.985) 
2.59 
(1.48) 
0.026 (0.896) 
2.27 
(1.23) 
0.510 (0.52) 6.164 (0.046) 
UPDRS item 21 
(speech) 
1.43 
(1.03) 
-0.092 
(0.693) 
0.75 
(0.93) 
0.140 (0.479) 
0.57 
(0.76) 
0.134 (0.649) 8.433 (0.015) 
UPDRS item 33a 
(rigidity) 
1.19 
(0.98) 
0.362 (0.106) 
0.54 
(0.64) 
0.074 (0.707) 
0.73 
(0.80) 
-0.037 
(0.895) 
6.489 (0.039) 
Zarit item 8 
(social life 
suffered) 
1.29 
(1.19) 
0.239 (0.296) 
0.62 
(0.80) 
0.159 (0.439) 
0.43 
(0.76) 
-0.127 (0.664) 7.319 (0.026) 
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Determinants of compliance 
A Kruskal-Wallis H test was run to determine if there were differences in usage between patients’ groups 
(low, moderate and high usage) based on demographics and total scores as well as on their scoring in the 
ordinal variables which are indicating symptoms (NMSS and UPDRS items), quality of life aspects (PDQ8 
and EQ-5D-5L items) and caregiver burden reasons (Zarit items). The distributions of usage were 
significantly different between groups for specific items of the scales and not for the total scores (Table 3).   
A linear regression was run to understand the effect of caregivers’ burden on system usage. Linearity was 
assessed with a scatterplot of Zarit_total against system usage with superimposed in which the regression 
line was plotted. Visual inspection of these two plots indicated a linear relationship between the variables. 
There was homoscedasticity and normality of the residuals. There were no outliers.  
The prediction equation was: usage = 48.31 + 1,51 * Zarit_total. Zarit_total statistically significantly 
predicted usage, F(1, 59) = 5.86, p < .019, accounting for 30% of the variation in usage with adjusted R2 = 
7.5%, a small size effect according to Cohen.  
A multiple regression analysis was run to determine how much of the variation in the system usage can be 
explained by the caregivers’ burden (Zarit total), Motor Aspects of Experiences of Daily Living (M-EDL, 
UPDRS-PART II) and patients self-rated health status (EQ-5D-5L). 
There was linearity as assessed by partial regression plots and a plot of studentized residuals against the 
predicted values. There was independence of residuals, as assessed by a Durbin-Watson statistic of 1.855, 
and homoscedasticity, as assessed by visual inspection of a plot of studentized residuals versus 
unstandardized predicted values. There was no evidence of multicollinearity, as assessed by tolerance 
values greater than 0.1. There were no studentized deleted residuals greater than ±3 standard deviations 
and values for Cook's distance above 1 as well as Leverage values greater than 0.2 (outliers). The 
assumption of normality was met, as assessed by a Q-Q Plot. The multiple regression model statistically 
significantly predicted Usage, F(3, 56) = 5.650, p = .002.  R for the overall model was 48.2% with an 
adjusted R2 of 19.1%, a medium size effect according to Cohen. All three variables added statistically 
significantly to the prediction, p < .05. Regression coefficients and standard errors can be found in Table 
4. 
Table 4: Summary of Multiple Regression Analysis. 
Model B Std. Error B Beta p (Significance) 
(Constant) 89.084 16.345  .000 
EQ_5D_5L_Total -6.022 1.925 -.465 .003 
Zarit_Total 1.651 .687 .331 .020 
UPDRS_II_Total 1.757 .847 .326 .043 
B = Unstandardized Regression Coefficient, Std. Error B = Standard error of the coefficient, Beta = Standardized Coefficient 
 
A binomial logistic regression was performed to ascertain the effects of caregivers’ burden (Zarit total), 
Motor Aspects of Experiences of Daily Living (M-EDL, UPDRS-PART II) and patients’ self-rated health 
status (EQ-5D-5L) on the likelihood of high system usage. Linearity of the continuous variables with 
respect to the logit of the dependent variable was assessed via the Box-Tidwell procedure. A Bonferroni 
correction was applied using all eight terms in the model resulting in statistical significance being accepted 
when p < .00833. Based on this assessment, all continuous independent variables were found to be linearly 
related to the logit of the dependent variable. There was one standardized residual. The logistic regression 
model was statistically significant, χ2(3) = 13.464, p = .004. The model explained 33.3% (Nagelkerke R2) 
of the variance in usage and correctly classified 74.5% of cases. Sensitivity was 80.8%, specificity was 
66.7%, positive predictive value was 75.0% and negative predictive value was 73.3%. Of the three predictor 
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variables, two were statistically significant:  caregivers’ burden and patients’ self-rated health status as 
shown in Table 5. Users with better self-rated health status had 1,5 times higher odds to exhibit higher 
system usage. Moreover, increasing caregivers’ burden was associated with an increased likelihood of 
higher system usage.  
Table 5: Summary of Binary Logistic Regression. 
 
B 
Std. 
Error B 
Wald df p (Significance) Odds ratio 
EQ_5D_5L_Total .396 .158 6.252 1 .012 1.485 
UPDRS_II_Total -.088 .057 2.395 1 .122 .916 
Zarit_Total -.122 .053 5.186 1 .023 .885 
Constant -1.294 1.119 1.338 1 .247 .274 
B = Unstandardized Regression Coefficient, Std. Error B = Standard error of the coefficient, Wald = Wald chi-square test, df = 
degrees of freedom for the Wald chi-square test,  
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Clinically meaningful data with ecological validity 
The method for the evaluation of tremor was presented in [19]. The limitation of this method was that the 
validation of accuracy was done with annotations by clinicians over specific, short periods in the controlled 
environment of a clinic, following  a specific protocol [16]. In this first data collection study, the sessions 
were filmed in order to confirm the annotations with external observers. With the data collected in the 
pilot study presented here, we were able to evaluate whether the method works for patients performing 
daily activities. Video at home was excluded due to study participants’ privacy concerns. The annotation 
was the perceived tremor as depicted in UPDRS item 2.10 (which indicates how the patient experienced 
tremor over the past week), the rest tremor amplitude in the left and right upper extremity as depicted in 
UPDRS item 3.17 (which allows the rater to gather observations on rest tremor that may appear at any time 
during the exam) and the constancy of rest tremor as depicted in UPDRS item 3.18 (which focuses on the 
constancy of rest tremor during the examination period when different body parts are variously at rest). 
All UPDRS items were assessed at the baseline visit, i.e. before the pilot usage of the system. Maximum of 
3.17a and 3.17b referring to rest tremor amplitude in upper extremities was also estimated as part of the 
analysis.  
50 cases were included in tremor analysis since for these cases more than 30 hours of sensor data were 
available from the pilot study and the results can be considered as reliable. The tremor was constantly 
evaluated at any moment data were available from the system with the method presented in [19] and this 
is the score depicted in Table 6. Bivariate correlations between UPDRS items scored be the clinicians at 
baseline and the tremor score with our method were calculated with Pearson’s.  
We notice that the mean score for no tremor is close to zero. This is due to the fact that some daily 
movements can simulate tremor and, as explained, the score was constantly calculated. Consistently, we 
noticed a small increase of mean score for slight tremor and a more significant increase for mild and 
moderate tremor.  
A Welch t-test was run to determine if there were differences in scores between groups and statistically 
significant differences confirm the discrimination between the no-tremor and tremor groups. 
Moreover, there is a statistically significant, strong positive correlation between the tremor score and 
amplitude and constancy of tremor as evaluated at baseline by the clinicians and a moderate positive 
correlation with tremor as perceived by the patient.  
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Table 6: Correlations between UPDRS tremor related items and our tremor method scores. 
  
2.10 (tremor as 
perceived by the 
patient) 
3.17-a (rest tremor 
amplitude – right 
upper extremity) 
3.17-b (rest tremor 
amplitude – left upper 
extremity) 
Max 3.17 
# of cases with UPDRS=0 21 39 38 32 
Mean Score for UPDRS=0 
with our method 
0.038 0.073 0.066 0.037 
Std. Dev. for UPDRS=0 cases 0.034 0.156 0.116 0.032 
# of cases  
with UPDRS=1 
18 8 8 12 
Mean Score for UPDRS=1 
with our method 
0.123 0.184 0.22 0.128 
Std. Dev. for UPDRS=1 cases 0.226 0.248 0.329 0.172 
# of cases with  
UPDRS>1 
11 3 4 6 
Mean Score for UPDRS>1 
with our method 
0.267 0.538 0.421 0.54 
Std. Dev. for UPDRS>1 cases 0.33 0.383 0.383 0.377 
AUC 0.643 0.887 0.783 0.871 
Welch's T-test, p-value for 
UPDRS=0 and UPDRS >1 
0.005 <0.001 <0.001 <0.001 
Welch's T-test, p-value for 
UPDRS=0 and UPDRS =1 
0.108 0.117 0.03 0.008 
Pearson  
Correlation 
0.378 0.544 0.468 0.711 
Pearson  
p-value 
0.007 <0.001 <0.001 <0.001 
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Discussion 
 
Principal Results 
The most important finding of our study is that patients with moderate PD, regardless of their age, gender, 
education, severity of symptoms, specific symptoms, perceived quality of life, caregiver burden etc. were 
compliant to use the system for 1-2 weeks. Overall, 87% of study participants (65 of the enrolled 75) were 
data contributors for 4,53 hours on average per day. They used the system for a median 11,57 days (Std. 
dev. 3,15).  
Regarding the compliance determinants, the regression analysis suggests that the best predictor associated 
with system usage was caregiver burden. The higher the burden the higher the usage, a finding emphasizing 
the role of caregivers in adherence to mHealth solutions including wearables. Moreover, the deterioration 
of caregiver’s social life seemed to be the most influential factor among Zarit items. The implication of 
these findings is that the moderate usage group demonstrated the lower caregiver burden.  
Motor Aspects of Experiences of Daily Living (M-EDL, UPDRS-PART II) also affect the usage of the system 
with users facing several motor problems in their ADL belonging to the high usage group and the rest 
reductively in the moderate and low groups. Especially speech problems seem to discriminate groups.  
Moreover, patients self-rated health status seems to predict high and moderate usage. Feeling 
pain/discomfort was the strongest individual predictor. 
Another objective of the study was to collect data that are clinically meaningful, i.e. data that the clinicians 
can use for the monitoring and the evaluation of symptoms when the patient is in his or her home 
environment. In this study we provide evidence of clinical validity and ecological effect of an algorithm 
derived from a single sensor on the wrist for detecting tremor in PD patients. The applications of such 
monitoring methods include patients that cannot properly report their symptoms either because they are 
newly diagnosed or because they find it difficult to characterize tremor or even differentiate tremor from 
dyskinesias. 
Following the paradigm of recent studies, PD_manager has built a large database for future development 
and testing of novel algorithms applied to sensor-derived data from PD patients during daily functioning. 
In total more than 2.700 hours of useful sensor data from the smartphone and MS band were collected and 
can be used for evaluating gait, freezing of gait, bradykinesia, tremor and dyskinesia or monitoring and 
evaluation of fluctuations in future studies. 
 
Comparison with Prior Work 
This study contributes to the growing evidence about the feasibility of mhealth for PD patients. It is aligned 
with the findings that there are no noteworthy variances in baseline characteristics (age, gender, education, 
disease duration and severity) that can explain compliance even in larger studies [4]. Findings such as 
highest compliance of older participants in one study [9], which can be attributed to more severe disease 
status and increased need for better management, and a negative impact of patients’ and caregivers’ 
education in this study, which can be the result of the lack of direct feedback from the system leading to 
limited self-management value, are worthy of further exploration.  
By including patients with moderate disease severity (H&Y was 3) and by exploring the determinants of 
their compliance, PD_manager complements most prior studies that recruited mostly the patients mildly 
affected (H&Y was 2 or less) [49-1113]. The high level of system usage and compliance of these more 
affected patients, as in previous studies, can be linked to factors including the simple and passive design of 
the patient’s app, which was basically providing a series of reminders for short motor and non-motor tasks, 
the insight in the condition that the patients and their caregivers expect as a result of using the system and 
the fact that the technology is considered as an extension of prescribing clinicians and thus as very 
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important for better care. PD_manager was used as a “PD-Holter”, i.e. in a similar context as [81013] and 
it complements the findings from previous studies [2459] which suggest that mhealth systems could be 
used both for short (1-2 weeks) and for long (6 months) term monitoring of PD patients, especially if their 
clinical condition is relatively mild. 
Moreover, our findings are consistent with the recent studies [20] showing patients’ attitude to technology 
use [21]. Our mhealth platform, as relevant studies suggest, can be an effective tool for the passive, 
unobtrusive monitoring and evaluation of symptoms [22], for defining new phenotypical biomarkers [23], 
for the detection of serious events such as falls [24], for the detection of worsening in the overall health 
status of the patients as well as for the provision of better disease management and improved care [25], 
the latter being already extensively studied in ongoing clinical trials (e.g. NCT03741920 and 
NCT02657655). Mobile health may also help rehabilitation [2627] and facilitate telemedicine since it 
enables home-based [28], multidisciplinary [29] approaches for the management of PD. Moreover, the 
system could be used for connecting and sharing health data promoting research in Parkinson’s [30], in 
line with EU priorities for enabling the digital transformation of health and care. Empowering citizens and 
promoting self- management is another important benefit of mhealth for PD patients [2]. Finally, mhealth 
can be used to provide decision support on the need for advanced treatments and their titration when they 
are applied [31].  
 
Limitations 
Limitations include the number of patients that used the system which, despite their excellent stratification 
that was preferred in this study over extended recruitment, should be increased in future studies to further 
establish the findings. The relatively preserved cognitive condition of study patients could be considered a 
limitation since cognitive deficits are common in advanced PD. Compliance was not calculated as the 
median percentage of the study period where accelerometer data were collected as in previous studies 
because the designs are different, and the technology limitations imposed a rather personalized usage of 
the system during the waking day. Another limitation is that compliance should also be assessed in 
repeated 10-14 days periods, at least twice a year, as the clinically meaningful use would demand, to 
evaluate the long-term effects in patients’ care. Finally, more workshops with clinicians for improving the 
use of the system in clinical practice are required. 
 
Conclusions 
mhealth for monitoring of PD patients’ symptoms is feasible, at least for a period of 2 weeks. With the data 
collected with mhealth, ecologically valid, accurate and objective monitoring and evaluation of tremor and 
other symptoms is feasible and future studies should confirm its efficiency to support clinical decisions 
and improve patients’ management. Future mheath systems should take into consideration and address 
the determinants of mhealth usage which include the subjective caregiver burden and especially suffered 
social life, the self-evaluation of the activities of daily life (ADLs) including speech and the overall patients’ 
self-rated health status with emphasis in pain and discomfort.  
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